Scientific publications

Sessink PJM, Nyulasi T, Haraldsson ELM, Rebic B. Reduction of contamination with antibiotics on surfaces and in environmental air in three European hospitals following implementation of a closed-system drug transfer device. Annals of Work Exposures and Health 2019;63(4):459-467.

Sessink PJM. Biomonitoring great, but do it the right way! J Oncol Pharm Practice 2018. Letter to the Editor. J Oncol Pharm Practice. 2019;25(1):246-247.

Gilbar PJ, Chambers CR, Vandenbroucke J, Sessink PJM, Tyler TG. How can the use of closed system transfer devices to facilitate sharing of drug vials be optimized to achieve maximum cost savings? J Oncol Pharm Practice. 2019;25(1):205-209.

Willaert W, Sessink P, Ceelen W. Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura and Peritoneum. January 2017. DOI: 101515/pp-2017-0018.

Sessink PJM, Leclercq GM, Wouters D, Halbardier L, Hammad C, Kassoul N. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. J Oncol Pharm Practice. 2014;21(2):118-127.

Sessink PJM. Selection of a closed-system drug transfer device related to toxicity and potential exposure of antineoplastic agents. Eur J Oncol Pharm. 2014;8(1):14-18.

Power LA, Sessink PJM, Gesy K, Charbonneau F. Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. Hosp Pharm. 2014;49(4):355-362.

Clark BA, Sessink PJM. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. J Oncol Pharm Practice. 2013;19(2):99-104.

Sessink PJM, Trahan J, Coyne JW. Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm.  2013;48(3):204-212.

Yuki M, Sekine S, Takase K, Ishida T, Sessink PJM. Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Practice. 2012;19(3):208-217.

Sessink PJM. Environmental contamination with cytostatic drugs: past, present, future. Safety Considerations in Oncology Pharmacy. Special Edition, Fall 2011:3-5.

Sessink PJM, Connor TH, Jorgenson JA, Tyler TG. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Practice. 2011;17(1):39-48.

Tanimura M, Yamada K, Sugiura S, Mori K, Nagata H, Tadokoro K, Miyake T, Hamaguchi Y, Sessink P, Nabeshima T. An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a Japanese community hospital designated for the treatment of cancer. J Health Sci. 2009;55(5):750-756.

Crauste-Manciet S, Sessink PJM, Ferrari S, Jommier JY, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg. 2005;49(7):619-628. 

Connor TH, Sessink PJM, Harrison BR, Pretty JR, Peters BD, Alfaro RM, Bilos A, Beckmann G, Bing MR, Anderson LM, DeChristoforo R. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm. 2005;62(5):475-484.

Connor TH, Van Balen P, Sessink PJ. Monitoring for hazardous drugs in the operating room. Ann Surg Oncol. 2003;10(7):821-822; reply 822-823.

Connor TH, Anderson RW, Sessink PJM, Spivey M. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm. 2002;59(1):68-72.

Kiffmeyer TK, Kube C, Opiolka S, Schmidt KG, Schöppe G, Sessink PJM. Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety. Pharm J. 2002;268:331-337. 

Sessink PJM, Bos RP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 1999;20(4):347-359.

Sessink PJM, Rolf ME, Rydèn NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999;34(11):1311-1317.

Connor TH, Anderson RW, Sessink PJM, Broadfield L, Power LA. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Heath Syst Pharm. 1999;56(14):1427-1432.

Bos RP, Sessink PJM. Biomonitoring of occupational exposure to cytostatic anticancer drugs. Rev Environ Health. 1997;12(1):43-58.

Sessink PJM, Verplanke AJW, Herber RFM, Bos RP. Occupational exposure to antineoplastic agents and parameters for renal dysfunction. Int Arch Occup Environ Health. 1997;69(3):215-218.

Sessink PJM, Wittenhorst BCJ, Anzion RBM, Bos RP. Exposure of pharmacy technicians to antineoplastic agents; reevaluation after additional protective measures. Arch Environ Health. 1997;52(3):240-244.

Sessink PJM. Monitoring of occupational exposure to antineoplastic agents. PhD thesis. University of Nijmegen, The Netherlands. 1996. ISBN 90-803205-1.

Sessink PJM, Vaes WHJ, van den Broek PHH, de Roos JHC, Noordhoek J, Bos RP. Influence of aroclor 1254, phenobarbital, ß-naphthoflavone, and alcohol pretreatment on the biotransformation of cyclophosphamide in male and female rats. Toxicology. 1996;112(2):141-150.

Sessink PJM, Kroese ED, van Kranen HJ, Bos RP. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1995;67(5):317-323.

Sessink PJM, Vaes WHJ, van den Broek PHH, Noordhoek J, Bos RP. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro. J Chromatogr. 1995;673(2):205-212.

Sessink PJM, Cerná M, Rössner P, Pastorková A, Bavarová H, Franková K,  Anzion RBM, Bos RP. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res. 1994;309(2):193-199.

Sessink PJM, van de Kerkhof MCA, Anzion RBM, Noordhoek J, Bos RP. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environ Health. 1994;49(3):165-169.

Sessink PJM, Timmermans JL, Anzion RBM, Bos RP. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. Determination of α-fluoro-ß-alanine in urine. J Occup Med. 1994;36(1):79-83.

Sessink PJM, Friemèl NSS, Anzion RBM, Bos RP. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health. 1994;65(6):401-403.

Sessink PJM, Scholtes MM, Anzion RBM, Bos RP. Determination of cy­clophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr. 1993;616(2):333-337.

Sessink PJM, de Roos JHC, Pierik FH, Anzion RBM, Bos RP. Occupatio­nal exposure of animal caretakers to cyclophosphamide. J Occup Med. 1993;35(1):47-52.

Sessink PJM, Boer KA, Scheefhals APH, Anzion RBM, Bos RP. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992;64(2):105-112. 

Sessink PJM, Anzion RBM, van den Broek PHH, Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992;14(1):16-22.

Dirven HAAM, de Bruijn AAGM, Sessink PJM, Jongeneelen FJ. Determination of the cytochrome P-450 IV marker w-hydroxylauric acid, by high-performance liquid chromatography and fluorimetric detection. J Chromatogr. 1991;564(1):266-271.

Sessink PJM, van den Broek PHH, Bos RP. Urinary cyclop­hosphamide excre­tion in rats after intratracheal, dermal, oral en intravenous administration of cyclop­hosphamide. J Appl Toxicol. 1991;11(2):125-128.

Lange JHM, Sessink PJM, Klunder AJH, Smits JMM, Bosman WP, Behm H, Beurskens PT. Crystal structure of ethyl-endo-tricyclo[,6]-deca-3,8-dien-5-one-2-carboxylate, C13H14O3. J Crystallogr Spectrosc Res. 1988;18(6):779-784.

Klunder AJH, Huizinga WB, Sessink PJM, Zwanenburg B. Enzymic optical resolution and vlash vacuum thermolysis in concert for the synthesis of optically active cyclopentenones. Tetrahedron Lett. 1987;28:357-360.


Other publications


Sessink P. Preventing exposure to cytotoxic drugs. Hospital Pharmacy Europe. 2016;83:15-18.

Sessink P. Monitoring of occupational exposure to antineoplastic agents. Dissertation 4 November 1996. University of Nijmegen, The Netherlands. ISBN 90-803205-1

Sessink PJM, Anzion RBM, Bos RP. Letter to the editor. Arch Environ Health. 1995;50(5):397.



Sessink P. Blootstelling aan cytostatica in ziekenhuizen een voordurend wereldwijd probleem. TCDD. 2014(2):22-23.

Bos RP, Sessink PJM, Anzion RBM. Ongecontroleerde verspreiding van cyclophosphamide in ziekenhuizen als bron van beroepsmatige blootstelling. Tijdsch Soc Gezondheidsz. 1996;74:259-266.

Sessink P, Anzion R, Bos R. Contaminatie oncolytica. Letter to the editor. Ziekenhuisfarmacie. 1995;11:77.

Sessink PJM, Bos RP. Monitoring van beroepsmatige blootstelling aan cytostatica. 1994. S184. Ministerie van Sociale Zaken en Werkgelegenheid.

Sessink PJM, Bos RP. Beroepsmatige blootstelling aan cytostatica. Arbovisie. 1993;9:1-5.

Sessink PJM, Bos RP. Verspreiding van cytostatica. Risico's voor blootstelling. Arbovisie. 1991;7:5-9.

Sessink PJM, Bos RP. Monitoring van beroepsmatige blootstelling aan cytostatica. Tijdschrift voor toegepaste Arbowetenschap 2. 1989;6:97-102.



Bussières JF, Sessink PJM, Prot-Labarthe S, Larocque D. Évaluation de l’exposition professionnelle aux antinéoplasiques dans une unité de pharmacie hospitalière. Arch Mal Prof Env. 2006;880-888.



Opiolka S, Kiffmeyer T, Kube C, Reinders M, Schöppe G, Schmidt KG, Sessink PJM. Geben die Filter Partikelsubstanz ab? Krankenhaustechnik. 1999;11:98-100.



Doktorn som hjälper doktor. Torslanda-Tidningen 23 maj 2018.